222 related articles for article (PubMed ID: 24402134)
1. The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Kelsey JE; Neville C
Psychopharmacology (Berl); 2014 Jun; 231(12):2405-15. PubMed ID: 24402134
[TBL] [Abstract][Full Text] [Related]
2. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
[TBL] [Abstract][Full Text] [Related]
3. Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Rentsch P; Stayte S; Morris GP; Vissel B
BMC Neurosci; 2019 Feb; 20(1):5. PubMed ID: 30760214
[TBL] [Abstract][Full Text] [Related]
4. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Chotibut T; Meadows S; Kasanga EA; McInnis T; Cantu MA; Bishop C; Salvatore MF
Mov Disord; 2017 Nov; 32(11):1547-1556. PubMed ID: 28631864
[TBL] [Abstract][Full Text] [Related]
5. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
6. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Dupre KB; Eskow KL; Steiniger A; Klioueva A; Negron GE; Lormand L; Park JY; Bishop C
Psychopharmacology (Berl); 2008 Jul; 199(1):99-108. PubMed ID: 18545986
[TBL] [Abstract][Full Text] [Related]
7. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
[TBL] [Abstract][Full Text] [Related]
8. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
11. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
12. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
[TBL] [Abstract][Full Text] [Related]
13. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
[TBL] [Abstract][Full Text] [Related]
14. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C
J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
[TBL] [Abstract][Full Text] [Related]
15. Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Dekundy A; Mela F; Hofmann M; Danysz W
J Neural Transm (Vienna); 2015 Jun; 122(6):809-18. PubMed ID: 25319446
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
17. Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Arakawa K; Yuge N; Maehara S
Pharmacol Rep; 2020 Apr; 72(2):443-448. PubMed ID: 32144743
[TBL] [Abstract][Full Text] [Related]
18. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
[TBL] [Abstract][Full Text] [Related]
19. The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Kelsey JE; Langelier NA; Oriel BS; Reedy C
Psychopharmacology (Berl); 2009 Jan; 201(4):529-39. PubMed ID: 18791705
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
